Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 5/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6854207 | 0.82 | MEN1 (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL28469736 | 0.81 | MEN1 (0.35) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL30302117 | 0.80 | ERN1 (0.59) | ERN1ALDH1A1 | |
| SCHEMBL28470496 | 0.79 | KMT2A (0.36) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL16399564 | 0.79 | LMNA (0.48) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL96494 | 0.78 | LMNA (0.57) | LMNAKMT2AMEN1THRBBLM | |
| Benzene SCHEMBL27923728 | 0.78 | LMNA (0.57) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL5711323 | 0.78 | LMNA (0.57) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL4032566 | 0.76 | LMNA (0.38) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL30721661 | 0.76 | LMNA (0.55) | LMNAKMT2AMEN1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101065366-A | Dibenzyl amine compounds and derivatives | PFIZER PROD INC (US) | 2007-10-31 | — | — | CN | claimed |
| EP-1817297-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Inc. (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006056854-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2006-06-01 | — | — | WO | claimed |
| CN-115697974-A | Imidazole 3-oxide derivative based ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| EP-3765453-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-105408325-B | cyanotriazole compounds | 大塚制药株式会社 | 2019-10-22 | — | — | CN | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| CN-102532162-A | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2012-07-04 | — | — | CN | disclosed |
| CN-102311401-A | CETP INHIBITORS | MERCK & CO INC | 2012-01-11 | — | — | CN | disclosed |
| CN-102304096-A | CETP inhibitors | MERCK SHARP & DOHME | 2012-01-04 | — | — | CN | disclosed |
| EP-1501509-A4 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| CN-101218223-A | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH CORP (US) | 2008-07-09 | — | — | CN | disclosed |
| CN-101065366-A | Dibenzyl amine compounds and derivatives | PFIZER PROD INC (US) | 2007-10-31 | — | — | CN | disclosed |
| CN-1980904-A | CETP inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
| EP-1501509-A2 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004024061-A2 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | CD274, PDCD1, PDCD1LG2 | LMNA 1405/4885KMT2A 3056/4885MEN1 1016/4885 |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | LMNA 1405/4885KMT2A 3056/4885MEN1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.